Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Goyal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lipika Goyal is medical oncologist in Palo Alto, CA and serves as the Director of Gastrointestinal Oncology at the Stanford Cancer Center. She received her medical degree from Harvard Medical School and has been in practice 11 years. She is runs clinical trials and does research in cholangiocarcinoma, and hepatocellular carcinoma. She has more than 100 publications and over 500 citings.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2007 - 2010
Harvard Medical SchoolClass of 2007
Certifications & Licensure
CA State Medical License 2023 - 2027
MA State Medical License 2012 - 2023
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Start of enrollment: 2019 Oct 07
Publications & Presentations
PubMed
- Pemigatinib for Previously Treated Metastatic or Unresectable Central Nervous System Tumors with FGFR Mutations or Rearrangements: FIGHT-207 Results.Iben Spanggaard, Marc Matrana, Caio Rocha Lima, Amit Mahipal, Maria Vieito
The Oncologist. 2025-10-16 - Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 ...James J Harding, Do-Youn Oh, Teresa Macarulla Mercade, Lipika Goyal, Andreas Varkaris
Clinical Cancer Research. 2025-09-30 - Disruption of fibroblast MYD88 signaling promotes antitumor immunity in pancreatic ductal adenocarcinoma.Maria Korah, Rosyli F Reveron-Thornton, Mahsa Fallah, Peter Y Xie, Amanda Gonçalves
Cell Reports. 2025-09-24
Journal Articles
- A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC)Hui Zheng, Rakesh K Jain, Lipika Goyal, Andrew X Zhu, Clinical Cancer Research
Press Mentions
Debate Over Adjuvant Therapy for Resectable Liver Cancer Divides ExpertsJanuary 31st, 2025- Understanding Genomic Correlates of Response and Acquired Resistance to FGFR InhibitorsJanuary 28th, 2025
- Taiho Oncology Announces Publication in the New England Journal of Medicine of Pivotal Data for Futibatinib in Previously Treated Patients with Metastatic Intrahepatic CholangiocarcinomaJanuary 18th, 2023
- Join now to see all
Other Languages
- Spanish, Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
